Paris and Evry (France), June 6, 2011 – Cellectis (Alternext: ALCLS), the genome engineering specialist, and VitamFero, a biotech company of the Genopole® portfolio developing new vaccines against parasite infections, announced the signing of a research, development and licensing partnership agreement. This agreement will grant VitamFero access to Cellectis’ proprietary meganuclease technology for the design and development of a new generation of living attenuated vaccines.Under this 5-year agreement, Cellectis will supply VitamFero with preselected méganucléases for initial use in the development of vaccines against parasites responsible for toxoplasmosis, neosporosis, and others...
[...]
About Cellectis
Cellectis improves life by applying its genome engineering expertise to a broad range of applications, including agriculture, bioresearch and human therapeutics. Cellectis is listed on the NYSE-Euronext Alternext market (code: ALCLS) in Paris.
About VitamFero
Created in 2005 and having just completed a significant raise of 1.1 M€, VitamFero exploits the breakthroughs jointly obtained and patented by CNRS, INRA and Université François Rabelais in Tours (France) in the domain of antiparasite vaccines, an area where needs are still largely unmet. VitamFero is built on a strong and validated scientific basis, based on the development of living parasite strains (i.e. Toxoplasma gondii, …), attenuated by complete and targeted deletion of virulence genes... [PDF] Cellectis' Press Release - PDF du communiqué de presse de VitamFero -
